Infectious disease clinics of North America

• 

  Año 2013, Vol. 27, Número 1. Dedicado a: Community-Acquired pneumonia: Controversies and questions

  • Is the Present Definition of Health Care�Associated Pneumonia the Best Way to Define Risk of Infection with Antibiotic-Resistant Pathogens?

    Vanessa Yap, Debapriya Datta, Mark L. Metersky

    • Resumen

    págs. 1-8

    

  • Biomarkers:: What is Their Benefit in the Identification of Infection, Severity Assessment, and Management of Community-acquired Pneumonia?

    Shweta Upadhyay, Michael S. Niederman

    • Resumen

    págs. 19-31

    

  • Which Is Best to Predict Clinical Response and Long-Term Outcomes?

    Timothy Wiemken, Robert Kelley, Julio Ramirez

    • Resumen

    págs. 33-48

    

  • What Is the Role of Newer Molecular Tests in the Management of CAP?

    Charlotte A. Gaydos

    • Resumen

    págs. 49-71

    

  • Guidelines and Quality Measures:: Do They Improve Outcomes of Patients with Community-Acquired Pneumonia?

    Jennie Johnstone, Lionel Mandell

    • Resumen

    págs. 71-86

    

  • What Is the Relevance of Antimicrobial Resistance on the Outcome of Community-Acquired Pneumonia Caused by Streptococcus pneumoniae? (Should Macrolide Monotherapy Be Used for Mild Pneumonia?)

    Donald E. Low

    • Resumen

    págs. 87-97

    

  • Does Empiric Therapy for Atypical Pathogens Improve Outcomes for Patients with CAP?

    Thomas M. File, Thomas J. Marrie

    • Resumen

    págs. 99-114

    

  • Does Empirical Therapy with a Fluoroquinolone or the Combination of a ?-Lactam Plus a Macrolide Result in Better Outcomes for Patients Admitted to the General Ward?

    Jörg Ruhe

    • Resumen

    págs. 115-132

    

  • What is the Best Antimicrobial Treatment for Severe Community-Acquired Pneumonia (Including the Role of Steroids and Statins and Other Immunomodulatory Agents)

    Oriol Sibila, Marcos I. Restrepo, Antonio Anzueto

    • Resumen

    págs. 133-147

    

  • How Important Are Anaerobic Bacteria in Aspiration Pneumonia:: When Should They Be Treated and What Is Optimal Therapy

    John G. Bartlett

    • Resumen

    págs. 149-155

    

  • How Important is Methicillin-Resistant Staphylococcus aureus as a Cause of Community-Acquired Pneumonia and What is Best Antimicrobial Therapy?

    Richard G. Wunderink

    • Resumen

    págs. 177-188

    

  • What Is the Best Approach to the Nonresponding Patient with Community-Acquired Pneumonia?

    Salvador Sialer, Adamantia Liapikou, Antoni Torres Martí

    • Resumen

    págs. 189-203

    

  • What is the Association of Cardiovascular Events with Clinical Failure in Patients with Community-Acquired Pneumonia?

    Paula Peyrani, Julio Ramirez

    • Resumen

    págs. 205-210

    

  • What is the Role of Antimicrobial Stewardship in Improving Outcomes of Patients with CAP?

    Sara Cosgrove, Veronique Nussenblatt, Edina Avdic

    • Resumen

    págs. 205-211

    

  • How Effective is Vaccination in Preventing Pneumococcal Disease?

    Daniel M. Musher

    • Resumen

    págs. 229-241